BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1265 related articles for article (PubMed ID: 31159869)

  • 1. PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer.
    Larsen TV; Hussmann D; Nielsen AL
    Cancer Commun (Lond); 2019 Jun; 39(1):30. PubMed ID: 31159869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High expression of PD-L1 mainly occurs in non-small cell lung cancer patients with squamous cell carcinoma or poor differentiation.
    Liu LU; Xie B; Zhu W; He Q; Zhou J; Liu S; Tao Y; Xiao D
    Oncol Res; 2023; 31(3):275-286. PubMed ID: 37305382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 and CD47 co-expression predicts survival and enlightens future dual-targeting immunotherapy in non-small cell lung cancer.
    Yang Z; Peng Y; Guo W; Xu J; Li L; Tian H; Li R; Liu L; Tan F; Gao S; He J
    Thorac Cancer; 2021 Jun; 12(11):1743-1751. PubMed ID: 33979899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of Responsiveness to PD-L1/PD-1 Inhibitors Using miRNA Profiles Associated With PD-L1 Expression in Lung Adenocarcinoma and Squamous Cell Carcinoma.
    Koh YW; Han JH; Haam S; Lee HW
    Anticancer Res; 2024 May; 44(5):2081-2089. PubMed ID: 38677736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer.
    Inoue Y; Yoshimura K; Mori K; Kurabe N; Kahyo T; Mori H; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
    Oncotarget; 2016 May; 7(22):32113-28. PubMed ID: 27050074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients.
    Ludovini V; Bianconi F; Siggillino A; Vannucci J; Baglivo S; Berti V; Tofanetti FR; Reda MS; Bellezza G; Mandarano M; Belladonna ML; Metro G; Chiari R; Sidoni A; Puma F; Minotti V; Roila F
    Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33671892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine.
    Wrangle J; Wang W; Koch A; Easwaran H; Mohammad HP; Vendetti F; Vancriekinge W; Demeyer T; Du Z; Parsana P; Rodgers K; Yen RW; Zahnow CA; Taube JM; Brahmer JR; Tykodi SS; Easton K; Carvajal RD; Jones PA; Laird PW; Weisenberger DJ; Tsai S; Juergens RA; Topalian SL; Rudin CM; Brock MV; Pardoll D; Baylin SB
    Oncotarget; 2013 Nov; 4(11):2067-79. PubMed ID: 24162015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 and PD-L2 immune checkpoint protein induction by type III interferon in non-small cell lung cancer cells.
    Larsen TV; Daugaard TF; Gad HH; Hartmann R; Nielsen AL
    Immunobiology; 2023 May; 228(3):152389. PubMed ID: 37146414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene landscape and correlation between B-cell infiltration and programmed death ligand 1 expression in lung adenocarcinoma patients from The Cancer Genome Atlas data set.
    Ho KH; Chang CJ; Huang TW; Shih CM; Liu AJ; Chen PH; Cheng KT; Chen KC
    PLoS One; 2018; 13(12):e0208459. PubMed ID: 30521597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Favorable outcome of patients with lung adenocarcinoma harboring POLE mutations and expressing high PD-L1.
    Liu L; Ruiz J; O'Neill SS; Grant SC; Petty WJ; Yang M; Chen K; Topaloglu U; Pasche B; Zhang W
    Mol Cancer; 2018 Apr; 17(1):81. PubMed ID: 29650000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential.
    Rotman J; den Otter LAS; Bleeker MCG; Samuels SS; Heeren AM; Roemer MGM; Kenter GG; Zijlmans HJMAA; van Trommel NE; de Gruijl TD; Jordanova ES
    Front Immunol; 2020; 11():596825. PubMed ID: 33424844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia-related lncRNAs to build prognostic classifier and reveal the immune characteristics of EGFR wild type and low expression of PD-L1 squamous and adenocarcinoma NSCLC.
    Zhao F; Wang M; Zhu J
    Cancer Med; 2021 Sep; 10(17):6099-6113. PubMed ID: 34250747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity.
    Tanegashima T; Togashi Y; Azuma K; Kawahara A; Ideguchi K; Sugiyama D; Kinoshita F; Akiba J; Kashiwagi E; Takeuchi A; Irie T; Tatsugami K; Hoshino T; Eto M; Nishikawa H
    Clin Cancer Res; 2019 Aug; 25(15):4808-4819. PubMed ID: 31076547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Prognostic Value of Measuring PD-L1 mRNA Expression Levels in Surgically Resected Non-Small Cell Lung Cancer.
    Kim GJ; Lee JH; Park WJ; Lee HW; Hwang IS; Lee DH
    Ann Clin Lab Sci; 2019 May; 49(3):317-323. PubMed ID: 31308030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiological Features of Programmed Cell Death-Ligand 2-positive Lung Adenocarcinoma: A Single-institution Retrospective Study.
    Takada K; Toyokawa G; Azuma K; Takamori S; Jogo T; Hirai F; Tagawa T; Kawahara A; Akiba J; Okamoto I; Nakanishi Y; Oda Y; Hoshino T; Maehara Y
    In Vivo; 2018; 32(6):1541-1550. PubMed ID: 30348714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study.
    Le Goux C; Damotte D; Vacher S; Sibony M; Delongchamps NB; Schnitzler A; Terris B; Zerbib M; Bieche I; Pignot G
    Urol Oncol; 2017 May; 35(5):257-263. PubMed ID: 28291636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of
    Erber R; Stöhr R; Herlein S; Giedl C; Rieker RJ; Fuchs F; Ficker JH; Hartmann A; Veltrup E; Wirtz RM; Brueckl WM
    Anticancer Res; 2017 Dec; 37(12):6771-6778. PubMed ID: 29187455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Tumor-Specific Super-Enhancer Drives Immune Evasion by Guiding Synchronous Expression of PD-L1 and PD-L2.
    Xu Y; Wu Y; Zhang S; Ma P; Jin X; Wang Z; Yao M; Zhang E; Tao B; Qin Y; Chen H; Liu A; Chen M; Xiao M; Lu C; Mao R; Fan Y
    Cell Rep; 2019 Dec; 29(11):3435-3447.e4. PubMed ID: 31825827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Extended PD-L2 Cytoplasmic Domain Results From Alternative Splicing in NSCLC Cells.
    Dietz LL; Furman NT; Larsen TV; Daugaard TF; Thomsen EA; Keller JL; Aagaard L; Sorensen BS; Nielsen AL
    J Immunother; 2022 Nov-Dec 01; 45(9):379-388. PubMed ID: 36036966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer.
    Calles A; Liao X; Sholl LM; Rodig SJ; Freeman GJ; Butaney M; Lydon C; Dahlberg SE; Hodi FS; Oxnard GR; Jackman DM; Jänne PA
    J Thorac Oncol; 2015 Dec; 10(12):1726-35. PubMed ID: 26473645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 64.